- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
268matching registry records
Snapshot timestampJuly 24, 2026 at 9:00 AM UTC
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightNCT07339423 / AMAZE 1 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 31,150 estimated | 71 recruiting72 listed / 9 countries | Jun 26, 2029estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07339423 ↗ |
| A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07481630 / AMAZE 5 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3400 estimated | 73 recruiting82 listed / 10 countries | Aug 14, 2028estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07481630 ↗ |
| AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight LossNCT07503210 / AMAZE 12 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3600 estimated | 67 recruiting72 listed / 12 countries | Jun 6, 2028estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07503210 ↗ |
| A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With ObesityNCT07508020 / Novo Nordisk A/S | RecruitingVerified 2026-04 | Phase 1120 estimated | 1 recruiting1 listed / 1 countries | Jan 19, 2028estimated | Apr 27, 2026ClinicalTrials.gov | Open NCT07508020 ↗ |
| AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07509307 / AMAZE 6 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3400 estimated | 73 recruiting81 listed / 11 countries | Aug 14, 2028estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07509307 ↗ |
| AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07533175 / AMAZE 2 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3630 estimated | 57 recruiting74 listed / 10 countries | Aug 7, 2028estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07533175 ↗ |
| Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 DiabetesNCT07535307 / Novo Nordisk A/S | RecruitingVerified 2026-04 | Phase 180 estimated | 1 recruiting1 listed / 1 countries | Nov 11, 2027estimated | Apr 24, 2026ClinicalTrials.gov | Open NCT07535307 ↗ |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 / HF-POLARIS / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 35,610 estimated | 470 recruiting839 listed / 27 countries | Jul 23, 2029estimated | Jul 15, 2026ClinicalTrials.gov | Open NCT07567001 ↗ |
| AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571005 / AMAZE 3 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3300 estimated | 55 recruiting80 listed / 10 countries | Jul 12, 2028estimated | Jul 13, 2026ClinicalTrials.gov | Open NCT07571005 ↗ |
| AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571109 / AMAZE 4 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3300 estimated | 67 recruiting92 listed / 10 countries | Jun 26, 2028estimated | Jul 13, 2026ClinicalTrials.gov | Open NCT07571109 ↗ |
| A Study on How NNC0174-1213 Works in People With Overweight or Obesity.NCT06719011 / Novo Nordisk A/S | RecruitingVerified 2025-05 | Phase 1177 estimated | 2 recruiting2 listed / 1 countries | Mar 26, 2026estimated | May 25, 2025ClinicalTrials.gov | Open NCT06719011 ↗ |
| The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432 / RAMBO / Novo Nordisk A/S | RecruitingVerified 2025-07 | Phase 1144 estimated | 1 recruiting1 listed / 1 countries | May 3, 2028estimated | Jul 25, 2025ClinicalTrials.gov | Open NCT07010432 ↗ |
| A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086 / Novo Nordisk A/S | RecruitingVerified 2025-10 | Phase 180 estimated | 2 recruiting2 listed / 1 countries | Oct 12, 2027estimated | Oct 8, 2025ClinicalTrials.gov | Open NCT07184086 ↗ |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3460 estimated | 16 recruiting120 listed / 26 countries | Mar 20, 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07253285 ↗ |
| A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560 / Novo Nordisk A/S | RecruitingVerified 2026-04 | Phase 1100 estimated | 1 recruiting1 listed / 1 countries | Jan 26, 2027estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT07411560 ↗ |
| Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195 / RASMUS / Novo Nordisk A/S | RecruitingVerified 2026-05 | Phase 1100 estimated | 1 recruiting1 listed / 1 countries | Apr 28, 2028estimated | May 7, 2026ClinicalTrials.gov | Open NCT07527195 ↗ |
| A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityNCT07557953 / Novo Nordisk A/S | RecruitingVerified 2026-05 | Phase 1120 estimated | 1 recruiting1 listed / 1 countries | Apr 13, 2027estimated | May 15, 2026ClinicalTrials.gov | Open NCT07557953 ↗ |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 32,500 estimated | 135 recruiting303 listed / 19 countries | Feb 23, 2028estimated | Jul 8, 2026ClinicalTrials.gov | Open NCT07564414 ↗ |
| A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNCT07597018 / Novo Nordisk A/S | RecruitingVerified 2026-06 | Phase 1234 estimated | 1 recruiting1 listed / 1 countries | May 28, 2027estimated | Jun 26, 2026ClinicalTrials.gov | Open NCT07597018 ↗ |
| Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNCT07607587 / Novo Nordisk A/S | RecruitingVerified 2026-06 | Phase 1114 estimated | 10 recruiting11 listed / 1 countries | Nov 19, 2027estimated | Jun 25, 2026ClinicalTrials.gov | Open NCT07607587 ↗ |
| A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityNCT07243171 / Hangzhou Sciwind Biosciences Co., Ltd. | RecruitingVerified 2025-10 | Phase 1 / Phase 284 estimated | 1 recruiting1 listed / 1 countries | Aug 3, 2026estimated | Jan 28, 2026ClinicalTrials.gov | Open NCT07243171 ↗ |
| A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure TherapyNCT07387094 / Hangzhou Sciwind Biosciences Co., Ltd. | RecruitingVerified 2026-01 | Phase 3140 estimated | 1 recruiting1 listed / 1 countries | Dec 16, 2027estimated | Apr 14, 2026ClinicalTrials.gov | Open NCT07387094 ↗ |
| A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure TherapyNCT07434050 / Hangzhou Sciwind Biosciences Co., Ltd. | RecruitingVerified 2026-01 | Phase 3140 estimated | 1 recruiting1 listed / 1 countries | Jun 19, 2028estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT07434050 ↗ |
| A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 21,481 estimated | 47 recruiting54 listed / 2 countries | Sep 2027estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06143956 ↗ |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 2200 estimated | 41 recruiting42 listed / 4 countries | Mar 2027estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07215559 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600 / ENLIGHTEN-2 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,035 estimated | 104 recruiting159 listed / 14 countries | Jan 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07282600 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 / ENLIGHTEN-1 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,980 estimated | 107 recruiting162 listed / 15 countries | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07321886 ↗ |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931 / ENLIGHTEN-4 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 95 recruiting161 listed / 15 countries | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07353931 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011 / ENLIGHTEN-3 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3800 estimated | 65 recruiting129 listed / 12 countries | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07369011 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 / ENLIGHTEN-6 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 108 recruiting173 listed / 13 countries | Jun 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07392190 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.NCT07401862 / Eli Lilly and Company | RecruitingVerified 2026-06 | Phase 136 estimated | 3 recruiting3 listed / 2 countries | Mar 2027estimated | Jun 4, 2026ClinicalTrials.gov | Open NCT07401862 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionNCT07426380 / Eli Lilly and Company | RecruitingVerified 2026-03 | Phase 128 estimated | 2 recruiting2 listed / 1 countries | Oct 2026estimated | Mar 13, 2026ClinicalTrials.gov | Open NCT07426380 ↗ |
| A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightNCT07589608 / Eli Lilly and Company | RecruitingVerified 2026-06 | Phase 2400 estimated | 40 recruiting40 listed / 1 countries | Sep 2027estimated | Jun 24, 2026ClinicalTrials.gov | Open NCT07589608 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Overweight or ObesityNCT07665879 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 1115 estimated | 1 recruiting2 listed / 2 countries | Aug 2027estimated | Jul 16, 2026ClinicalTrials.gov | Open NCT07665879 ↗ |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 / Enith1 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 32,000 estimated | 164 recruiting164 listed / 19 countries | Jul 24, 2028estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07351045 ↗ |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 / Enith2 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 31,600 estimated | 162 recruiting163 listed / 19 countries | Aug 7, 2028estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07351058 ↗ |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese ParticipantsNCT07626515 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 136 estimated | 1 recruiting1 listed / 1 countries | Apr 30, 2027estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07626515 ↗ |
| A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesNCT07670416 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 3300 estimated | 12 recruiting12 listed / 1 countries | Feb 24, 2028estimated | Jul 14, 2026ClinicalTrials.gov | Open NCT07670416 ↗ |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 / MARITIME-CV / Amgen | RecruitingVerified 2026-07 | Phase 312,800 estimated | 776 recruiting782 listed / 36 countries | Jun 30, 2028estimated | Jul 24, 2026ClinicalTrials.gov | Open NCT07037433 ↗ |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 / MARITIME-HF / Amgen | RecruitingVerified 2026-06 | Phase 35,056 estimated | 624 recruiting628 listed / 34 countries | Jun 30, 2028estimated | Jul 2, 2026ClinicalTrials.gov | Open NCT07037459 ↗ |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686 / MARITIME-OSA-1 / Amgen | RecruitingVerified 2026-06 | Phase 3250 estimated | 60 recruiting60 listed / 11 countries | Sep 29, 2027estimated | Jun 12, 2026ClinicalTrials.gov | Open NCT07225686 ↗ |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyNCT07226765 / MARITIME-OSA-2 / Amgen | RecruitingVerified 2026-06 | Phase 3250 estimated | 54 recruiting54 listed / 11 countries | Sep 29, 2027estimated | Jun 12, 2026ClinicalTrials.gov | Open NCT07226765 ↗ |
| A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightNCT07441252 / Amgen | RecruitingVerified 2026-06 | Phase 2180 estimated | 23 recruiting23 listed / 1 countries | Sep 29, 2027estimated | Jun 18, 2026ClinicalTrials.gov | Open NCT07441252 ↗ |
| Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399 / Amgen | RecruitingVerified 2026-07 | Phase 3300 estimated | 44 recruiting44 listed / 2 countries | Jan 3, 2028estimated | Jul 23, 2026ClinicalTrials.gov | Open NCT07575399 ↗ |
| Efficacy of Mazdutide for Treating PCOSNCT06519656 / Shanghai Zhongshan Hospital | RecruitingVerified 2024-10 | Phase 1 / Phase 250 estimated | 1 recruiting1 listed / 1 countries | Dec 31, 2025estimated | Oct 24, 2024ClinicalTrials.gov | Open NCT06519656 ↗ |
| A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityNCT06862908 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2025-07 | Phase 2141 estimated | 1 recruiting1 listed / 1 countries | Sep 24, 2026estimated | Jul 11, 2025ClinicalTrials.gov | Open NCT06862908 ↗ |
| A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2NCT06931028 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2025-06 | Phase 3260 estimated | 1 recruiting1 listed / 1 countries | May 7, 2027estimated | Jun 29, 2025ClinicalTrials.gov | Open NCT06931028 ↗ |
| A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT06937749 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2025-11 | Phase 2165 estimated | 1 recruiting1 listed / 1 countries | Apr 30, 2026estimated | Nov 20, 2025ClinicalTrials.gov | Open NCT06937749 ↗ |
| GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)NCT07083154 / The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | RecruitingVerified 2026-03 | Phase 3420 estimated | 6 recruiting8 listed / 1 countries | Aug 1, 2029estimated | Mar 5, 2026ClinicalTrials.gov | Open NCT07083154 ↗ |
| A Study of IBI362 in Chinese Adolescents With Obesity or OverweightNCT07255209 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2026-01 | Phase 3180 estimated | 1 recruiting1 listed / 1 countries | Oct 31, 2027estimated | Jan 8, 2026ClinicalTrials.gov | Open NCT07255209 ↗ |
| Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityNCT07469800 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2026-05 | Phase 3336 estimated | 1 recruiting1 listed / 1 countries | Aug 1, 2026estimated | May 27, 2026ClinicalTrials.gov | Open NCT07469800 ↗ |
| ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementNCT07517042 / Shanghai Zhongshan Hospital | RecruitingVerified 2025-12 | Not applicable420 estimated | 13 recruiting13 listed / 1 countries | Dec 2028estimated | Apr 8, 2026ClinicalTrials.gov | Open NCT07517042 ↗ |
| GLP-1 Therapy After Bariatric Surgery in Chinese Patients With ObesityNCT07633639 / China-Japan Friendship Hospital | RecruitingVerified 2026-05 | Not applicable200 estimated | 1 recruiting1 listed / 1 countries | May 1, 2028estimated | Jun 8, 2026ClinicalTrials.gov | Open NCT07633639 ↗ |
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)NCT07009860 / Altimmune, Inc. | RecruitingVerified 2026-03 | Phase 2100 estimated | 8 recruiting43 listed / 2 countries | Mar 31, 2027estimated | Mar 20, 2026ClinicalTrials.gov | Open NCT07009860 ↗ |
| Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum DisorderNCT06951854 / Neuroventi Inc. | RecruitingVerified 2025-04 | Phase 2105 estimated | 1 recruiting1 listed / 1 countries | Sep 1, 2025estimated | Apr 30, 2025ClinicalTrials.gov | Open NCT06951854 ↗ |
| Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic FunctionNCT07682818 / Zealand Pharma | RecruitingVerified 2026-06 | Phase 136 estimated | 3 recruiting3 listed / 2 countries | Apr 12, 2027estimated | Jul 6, 2026ClinicalTrials.gov | Open NCT07682818 ↗ |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 34,500 estimated | 449 recruiting563 listed / 34 countries | Aug 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07165028 ↗ |
| Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447 / GZBF / Hudson Biotech | RecruitingVerified 2026-03 | Phase 2300 estimated | 1 recruiting1 listed / 1 countries | Mar 14, 2027estimated | Mar 12, 2026ClinicalTrials.gov | Open NCT07467447 ↗ |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,800 estimated | 430 recruiting525 listed / 36 countries | Dec 27, 2031estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632444 ↗ |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisNCT06632457 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,590 estimated | 343 recruiting444 listed / 36 countries | Jun 5, 2029estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632457 ↗ |
| A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyNCT07407348 / Boehringer Ingelheim | RecruitingVerified 2026-06 | Phase 180 estimated | 1 recruiting1 listed / 1 countries | Jan 26, 2027estimated | Jun 16, 2026ClinicalTrials.gov | Open NCT07407348 ↗ |
| AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07400107 / AMAZE 8 / Novo Nordisk A/S | Not yet recruitingVerified 2026-03 | Phase 31,000 estimated | 0 recruiting120 listed / 14 countries | Dec 12, 2028estimated | Mar 12, 2026ClinicalTrials.gov | Open NCT07400107 ↗ |
| A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver FunctionNCT07587710 / Novo Nordisk A/S | Not yet recruitingVerified 2026-05 | Phase 135 estimated | 0 recruiting2 listed / 1 countries | Dec 1, 2027estimated | May 14, 2026ClinicalTrials.gov | Open NCT07587710 ↗ |
| AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose WeightNCT07668401 / AMAZE 13 / Novo Nordisk A/S | Not yet recruitingVerified 2026-07 | Phase 3400 estimated | 0 recruiting41 listed / 5 countries | Jan 11, 2029estimated | Jul 21, 2026ClinicalTrials.gov | Open NCT07668401 ↗ |
| A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideNCT07668414 / AMAZE 7 / Novo Nordisk A/S | Not yet recruitingVerified 2026-06 | Phase 3650 estimated | 0 recruiting46 listed / 1 countries | Oct 10, 2028estimated | Jun 25, 2026ClinicalTrials.gov | Open NCT07668414 ↗ |
| AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightNCT07720271 / AMAZE 9 / Novo Nordisk A/S | Not yet recruitingVerified 2026-07 | Phase 3950 estimated | 0 recruiting42 listed / 1 countries | Jun 27, 2028estimated | Jul 22, 2026ClinicalTrials.gov | Open NCT07720271 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 / REIMAGINEYOUNG / Novo Nordisk A/S | Not yet recruitingVerified 2026-05 | Phase 380 estimated | 0 recruiting56 listed / 10 countries | Sep 7, 2029estimated | May 28, 2026ClinicalTrials.gov | Open NCT07282613 ↗ |
| A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07553299 / Verdiva Bio Dev Limited | Not yet recruitingVerified 2026-06 | Phase 2120 estimated | 0 recruiting17 listed / 1 countries | Nov 30, 2026estimated | Jun 3, 2026ClinicalTrials.gov | Open NCT07553299 ↗ |
| A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or OverweightNCT07628127 / Verdiva Bio Dev Limited | Not yet recruitingVerified 2026-05 | Phase 1336 estimated | 0 recruiting0 listed / 0 countries | Mar 2028estimated | Jun 4, 2026ClinicalTrials.gov | Open NCT07628127 ↗ |
| A Study of Eloralintide (LY3841136) in Healthy ParticipantsNCT07701083 / Eli Lilly and Company | Not yet recruitingVerified 2026-07 | Phase 158 estimated | 0 recruiting2 listed / 1 countries | Oct 2026estimated | Jul 14, 2026ClinicalTrials.gov | Open NCT07701083 ↗ |
| A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightNCT07589686 / ZYNERGY / Hoffmann-La Roche | Not yet recruitingVerified 2026-07 | Phase 2486 estimated | 0 recruiting0 listed / 0 countries | Nov 12, 2027estimated | Jul 7, 2026ClinicalTrials.gov | Open NCT07589686 ↗ |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)NCT07684144 / Amgen | Not yet recruitingVerified 2026-06 | Phase 3950 estimated | 0 recruiting0 listed / 0 countries | Dec 26, 2027estimated | Jul 6, 2026ClinicalTrials.gov | Open NCT07684144 ↗ |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235 / Amgen | Not yet recruitingVerified 2026-06 | Phase 33,200 estimated | 0 recruiting0 listed / 0 countries | Dec 26, 2027estimated | Jul 6, 2026ClinicalTrials.gov | Open NCT07684235 ↗ |
| Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe ObesityNCT07135141 / SMART / Beijing Friendship Hospital | Not yet recruitingVerified 2025-08 | Not applicable256 estimated | 0 recruiting14 listed / 1 countries | Sep 30, 2027estimated | Aug 21, 2025ClinicalTrials.gov | Open NCT07135141 ↗ |
| A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorNCT07417306 / Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruitingVerified 2026-02 | Phase 3912 estimated | 0 recruiting1 listed / 1 countries | Aug 30, 2027estimated | Feb 18, 2026ClinicalTrials.gov | Open NCT07417306 ↗ |
| Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)NCT07654062 / DREAM-PRE / Shandong Provincial Hospital | Not yet recruitingVerified 2026-06 | Phase 4150 estimated | 0 recruiting1 listed / 1 countries | Jun 2028estimated | Jun 17, 2026ClinicalTrials.gov | Open NCT07654062 ↗ |
| Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityNCT07657676 / China National Center for Cardiovascular Diseases | Not yet recruitingVerified 2026-06 | Phase 4116 estimated | 0 recruiting1 listed / 1 countries | Oct 31, 2027estimated | Jun 18, 2026ClinicalTrials.gov | Open NCT07657676 ↗ |
| Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With SemaglutideNCT07713992 / Tianjin Medical University | Not yet recruitingVerified 2026-07 | Not applicable72 estimated | 0 recruiting0 listed / 0 countries | Dec 31, 2027estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07713992 ↗ |
| Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)NCT07718126 / PRIME / West China Hospital | Not yet recruitingVerified 2026-07 | Phase 2 / Phase 360 estimated | 0 recruiting3 listed / 1 countries | Aug 31, 2028estimated | Jul 21, 2026ClinicalTrials.gov | Open NCT07718126 ↗ |
| Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseaseNCT07206290 / ARTIST-CKD / University Medical Center Groningen | Not yet recruitingVerified 2025-08 | Phase 2120 estimated | 0 recruiting0 listed / 0 countries | Nov 30, 2027estimated | Oct 3, 2025ClinicalTrials.gov | Open NCT07206290 ↗ |
| A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 / REDEFINE 1 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 33,400 estimated | 0 recruiting256 listed / 23 countries | Oct 30, 2024actual | Jul 17, 2026ClinicalTrials.gov | Open NCT05567796 ↗ |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 / REDEFINE 3 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 37,101 actual | 0 recruiting633 listed / 25 countries | Sep 1, 2027estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT05669755 ↗ |
| A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449 / Novo Nordisk A/S | Active, not recruitingVerified 2026-01 | Phase 3400 estimated | 0 recruiting36 listed / 6 countries | Aug 28, 2028estimated | Jan 20, 2026ClinicalTrials.gov | Open NCT06780449 ↗ |
| A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 / Novo Nordisk A/S | Active, not recruitingVerified 2025-12 | Phase 2142 actual | 0 recruiting54 listed / 7 countries | Aug 21, 2026estimated | Dec 5, 2025ClinicalTrials.gov | Open NCT06797869 ↗ |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 3609 actual | 0 recruiting46 listed / 1 countries | Mar 1, 2027estimated | Jul 24, 2026ClinicalTrials.gov | Open NCT07011667 ↗ |
| Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642 / RENEW 1 / Novo Nordisk A/S | Active, not recruitingVerified 2026-06 | Phase 3300 estimated | 0 recruiting40 listed / 10 countries | May 11, 2027estimated | Jun 30, 2026ClinicalTrials.gov | Open NCT07220642 ↗ |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759 / RENEW 2 / Novo Nordisk A/S | Active, not recruitingVerified 2026-04 | Phase 3330 estimated | 0 recruiting67 listed / 11 countries | May 12, 2027estimated | Apr 21, 2026ClinicalTrials.gov | Open NCT07220759 ↗ |
| A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 150 estimated | 0 recruiting1 listed / 1 countries | Sep 3, 2026estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07605052 ↗ |
| A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)NCT07073417 / Hangzhou Sciwind Biosciences Co., Ltd. | Active, not recruitingVerified 2025-07 | Phase 2163 actual | 0 recruiting1 listed / 1 countries | Feb 27, 2027estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT07073417 ↗ |
| A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07281937 / EVOLVE-2 / Verdiva Bio Dev Limited | Active, not recruitingVerified 2026-06 | Phase 2206 actual | 0 recruiting22 listed / 1 countries | Jul 2026estimated | Jun 3, 2026ClinicalTrials.gov | Open NCT07281937 ↗ |
| A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 2367 actual | 0 recruiting52 listed / 2 countries | Jul 1, 2026actual | Jul 17, 2026ClinicalTrials.gov | Open NCT06603571 ↗ |
| A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusNCT06628362 / Carmot Therapeutics, Inc. | Active, not recruitingVerified 2026-06 | Phase 2447 actual | 0 recruiting70 listed / 6 countries | May 29, 2026actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06628362 ↗ |
| A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)NCT06660173 / Amgen | Active, not recruitingVerified 2025-11 | Phase 2409 actual | 0 recruiting96 listed / 14 countries | Oct 6, 2025actual | Nov 25, 2025ClinicalTrials.gov | Open NCT06660173 ↗ |
| Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 / MARITIME-1 / Amgen | Active, not recruitingVerified 2025-10 | Phase 33,853 actual | 0 recruiting243 listed / 17 countries | Jan 21, 2027estimated | Oct 20, 2025ClinicalTrials.gov | Open NCT06858839 ↗ |
| Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878 / MARITIME-2 / Amgen | Active, not recruitingVerified 2025-12 | Phase 31,105 actual | 0 recruiting187 listed / 13 countries | Jan 21, 2027estimated | Dec 31, 2025ClinicalTrials.gov | Open NCT06858878 ↗ |
| Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity DiseaseNCT06987695 / MARITIME-3-J / Amgen | Active, not recruitingVerified 2025-12 | Phase 3279 actual | 0 recruiting30 listed / 1 countries | Apr 27, 2027estimated | Dec 17, 2025ClinicalTrials.gov | Open NCT06987695 ↗ |
| A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusNCT07160257 / Amgen | Active, not recruitingVerified 2026-06 | Phase 156 actual | 0 recruiting1 listed / 1 countries | Nov 15, 2026estimated | Jun 12, 2026ClinicalTrials.gov | Open NCT07160257 ↗ |
| Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityNCT07229157 / Amgen | Active, not recruitingVerified 2026-01 | Phase 181 actual | 0 recruiting2 listed / 1 countries | Aug 26, 2026estimated | Jan 23, 2026ClinicalTrials.gov | Open NCT07229157 ↗ |
| Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityNCT07523711 / Amgen | Active, not recruitingVerified 2026-07 | Phase 149 actual | 0 recruiting2 listed / 1 countries | Nov 18, 2026estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07523711 ↗ |
| A Study of IBI362 9 mg in Chinese Adults With ObesityNCT06164873 / Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruitingVerified 2024-08 | Phase 3462 actual | 0 recruiting1 listed / 1 countries | Jun 27, 2025estimated | Aug 27, 2024ClinicalTrials.gov | Open NCT06164873 ↗ |
| A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）NCT06884293 / Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruitingVerified 2026-05 | Phase 3479 actual | 0 recruiting1 listed / 1 countries | Dec 31, 2026estimated | May 12, 2026ClinicalTrials.gov | Open NCT06884293 ↗ |
| Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityNCT07000955 / Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruitingVerified 2025-12 | Phase 1 / Phase 298 actual | 0 recruiting1 listed / 1 countries | Sep 30, 2026estimated | Dec 15, 2025ClinicalTrials.gov | Open NCT07000955 ↗ |
| RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513 / Altimmune, Inc. | Active, not recruitingVerified 2025-11 | Phase 2100 actual | 0 recruiting12 listed / 1 countries | May 2026estimated | Nov 19, 2025ClinicalTrials.gov | Open NCT06987513 ↗ |
| Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842 / Zealand Pharma | Active, not recruitingVerified 2026-01 | Phase 2221 actual | 0 recruiting48 listed / 1 countries | Aug 13, 2026estimated | Jan 15, 2026ClinicalTrials.gov | Open NCT06926842 ↗ |
| A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 / TRIUMPH-3 / Eli Lilly and Company | Active, not recruitingVerified 2026-05 | Phase 31,946 actual | 0 recruiting169 listed / 10 countries | Apr 16, 2026actual | May 22, 2026ClinicalTrials.gov | Open NCT05882045 ↗ |
| A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 / TRIUMPH-2 / Eli Lilly and Company | Active, not recruitingVerified 2026-04 | Phase 31,000 estimated | 0 recruiting98 listed / 8 countries | May 2026estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT05929079 ↗ |
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 / Eli Lilly and Company | Active, not recruitingVerified 2026-04 | Phase 31,250 estimated | 0 recruiting77 listed / 5 countries | Aug 2026estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT06260722 ↗ |
| Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 3320 estimated | 0 recruiting76 listed / 7 countries | Oct 2026estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06297603 ↗ |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 310,000 estimated | 0 recruiting743 listed / 27 countries | Feb 2029estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06383390 ↗ |
| A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383 / TRIUMPH-5 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 3800 estimated | 0 recruiting65 listed / 5 countries | Nov 2026estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06662383 ↗ |
| A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268 / TRIUMPH-6 / Eli Lilly and Company | Active, not recruitingVerified 2026-02 | Phase 3643 estimated | 0 recruiting53 listed / 3 countries | Apr 2028estimated | Mar 3, 2026ClinicalTrials.gov | Open NCT06859268 ↗ |
| A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 195 estimated | 0 recruiting1 listed / 1 countries | Dec 2026estimated | Jul 16, 2026ClinicalTrials.gov | Open NCT06982859 ↗ |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 / TRIUMPH-7 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 3586 estimated | 0 recruiting40 listed / 4 countries | Sep 2027estimated | Jul 23, 2026ClinicalTrials.gov | Open NCT07035093 ↗ |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 / TRIUMPH-8 / Eli Lilly and Company | Active, not recruitingVerified 2026-04 | Phase 3250 estimated | 0 recruiting31 listed / 2 countries | Jul 2027estimated | Apr 17, 2026ClinicalTrials.gov | Open NCT07232719 ↗ |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415 / TRIUMPH-9 / Eli Lilly and Company | Active, not recruitingVerified 2026-06 | Phase 3600 estimated | 0 recruiting35 listed / 3 countries | Oct 2028estimated | Jun 9, 2026ClinicalTrials.gov | Open NCT07357415 ↗ |
| A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverNCT05202353 / Boehringer Ingelheim | Active, not recruitingVerified 2026-07 | Phase 129 actual | 0 recruiting1 listed / 1 countries | Dec 2, 2026estimated | Jul 22, 2026ClinicalTrials.gov | Open NCT05202353 ↗ |
| A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityNCT06745284 / Boehringer Ingelheim | Active, not recruitingVerified 2026-05 | Phase 164 actual | 0 recruiting2 listed / 1 countries | Jan 8, 2027estimated | May 12, 2026ClinicalTrials.gov | Open NCT06745284 ↗ |
| A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyNCT07221591 / Boehringer Ingelheim | Active, not recruitingVerified 2026-03 | Phase 1100 actual | 0 recruiting2 listed / 1 countries | Aug 4, 2026estimated | Mar 13, 2026ClinicalTrials.gov | Open NCT07221591 ↗ |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383 / Viking Therapeutics, Inc. | Active, not recruitingVerified 2026-04 | Phase 31,100 estimated | 0 recruiting127 listed / 2 countries | Jul 1, 2027estimated | Apr 7, 2026ClinicalTrials.gov | Open NCT07104383 ↗ |
| VK2735 for Weight Management Phase 3NCT07104500 / VANQUISH 1 / Viking Therapeutics, Inc. | Active, not recruitingVerified 2025-11 | Phase 34,500 estimated | 0 recruiting137 listed / 2 countries | Jul 1, 2027estimated | Nov 24, 2025ClinicalTrials.gov | Open NCT07104500 ↗ |
| Provide Pre-approval Expanded Access of LY3437943NCT07629401 / Eli Lilly and Company | AvailableVerified 2026-06 | Not applicableEnrollment not stated | 0 recruiting0 listed / 0 countries | Not statedType not stated | Jun 5, 2026ClinicalTrials.gov | Open NCT07629401 ↗ |
| A Research Study on How NNC0487-0111 Works in People With Overweight or ObesityNCT05369390 / Novo Nordisk A/S | CompletedVerified 2025-06 | Phase 1144 actual | 0 recruiting2 listed / 1 countries | Jan 9, 2024actual | Jun 15, 2025ClinicalTrials.gov | Open NCT05369390 ↗ |
| A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With ObesityNCT06049329 / Novo Nordisk A/S | CompletedVerified 2025-03 | Phase 136 actual | 0 recruiting1 listed / 1 countries | Dec 15, 2023actual | Mar 5, 2025ClinicalTrials.gov | Open NCT06049329 ↗ |
| A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the SkinNCT06064006 / Novo Nordisk A/S | CompletedVerified 2025-11 | Phase 2125 actual | 0 recruiting2 listed / 1 countries | Nov 27, 2024actual | Nov 19, 2025ClinicalTrials.gov | Open NCT06064006 ↗ |
| A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become PregnantNCT06461039 / Novo Nordisk A/S | CompletedVerified 2025-05 | Phase 143 actual | 0 recruiting1 listed / 1 countries | Mar 16, 2025actual | May 8, 2025ClinicalTrials.gov | Open NCT06461039 ↗ |
| A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or ObesityNCT06478563 / Novo Nordisk A/S | CompletedVerified 2025-08 | Phase 1133 actual | 0 recruiting1 listed / 1 countries | Jun 5, 2025actual | Aug 11, 2025ClinicalTrials.gov | Open NCT06478563 ↗ |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesNCT06542874 / Novo Nordisk A/S | CompletedVerified 2025-12 | Phase 2448 actual | 0 recruiting119 listed / 11 countries | Oct 1, 2025actual | Dec 29, 2025ClinicalTrials.gov | Open NCT06542874 ↗ |
| A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney FunctionNCT06559527 / Novo Nordisk A/S | CompletedVerified 2025-03 | Phase 142 actual | 0 recruiting1 listed / 1 countries | Feb 24, 2025actual | Mar 30, 2025ClinicalTrials.gov | Open NCT06559527 ↗ |
| A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral DosingNCT06820476 / Novo Nordisk A/S | CompletedVerified 2025-08 | Phase 129 actual | 0 recruiting2 listed / 1 countries | May 14, 2025actual | Aug 20, 2025ClinicalTrials.gov | Open NCT06820476 ↗ |
| A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.NCT07121153 / Novo Nordisk A/S | CompletedVerified 2026-02 | Phase 136 actual | 0 recruiting1 listed / 1 countries | Dec 20, 2025actual | Feb 17, 2026ClinicalTrials.gov | Open NCT07121153 ↗ |
| Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male SubjectsNCT02300844 / Novo Nordisk A/S | CompletedVerified 2018-01 | Phase 154 actual | 0 recruiting1 listed / 1 countries | Mar 21, 2016actual | Jan 24, 2018ClinicalTrials.gov | Open NCT02300844 ↗ |
| Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or OverweightNCT02958085 / Novo Nordisk A/S | CompletedVerified 2018-01 | Phase 196 actual | 0 recruiting1 listed / 1 countries | Jan 24, 2018actual | Feb 1, 2018ClinicalTrials.gov | Open NCT02958085 ↗ |
| A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or ObeseNCT03600480 / Novo Nordisk A/S | CompletedVerified 2021-11 | Phase 196 actual | 0 recruiting1 listed / 1 countries | Jun 12, 2020actual | Nov 17, 2021ClinicalTrials.gov | Open NCT03600480 ↗ |
| First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.NCT03617081 / Novo Nordisk A/S | CompletedVerified 2020-01 | Phase 140 actual | 0 recruiting1 listed / 1 countries | Dec 13, 2018actual | Jan 10, 2020ClinicalTrials.gov | Open NCT03617081 ↗ |
| A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With ObesityNCT03787225 / Novo Nordisk A/S | CompletedVerified 2019-06 | Phase 166 actual | 0 recruiting1 listed / 1 countries | Jun 4, 2019actual | Jun 24, 2019ClinicalTrials.gov | Open NCT03787225 ↗ |
| Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.NCT03856047 / Novo Nordisk A/S | CompletedVerified 2024-07Registry results posted | Phase 2706 actual | 0 recruiting54 listed / 10 countries | Mar 2, 2020actual | Jul 5, 2024ClinicalTrials.gov | Open NCT03856047 ↗ |
| Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become PregnantNCT04074174 / Novo Nordisk A/S | CompletedVerified 2022-01 | Phase 131 actual | 0 recruiting1 listed / 1 countries | Mar 6, 2020actual | Jan 10, 2022ClinicalTrials.gov | Open NCT04074174 ↗ |
| A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney FunctionNCT04209049 / Novo Nordisk A/S | CompletedVerified 2021-01 | Phase 133 actual | 0 recruiting2 listed / 1 countries | Jan 5, 2021actual | Jan 26, 2021ClinicalTrials.gov | Open NCT04209049 ↗ |
| A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or ObesityNCT04940078 / Novo Nordisk A/S | CompletedVerified 2025-12 | Phase 140 actual | 0 recruiting2 listed / 2 countries | Jan 19, 2022actual | Dec 12, 2025ClinicalTrials.gov | Open NCT04940078 ↗ |
| Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 DiabetesNCT04982575 / Novo Nordisk A/S | CompletedVerified 2025-12Registry results posted | Phase 292 actual | 0 recruiting23 listed / 1 countries | Jul 7, 2022actual | Dec 23, 2025ClinicalTrials.gov | Open NCT04982575 ↗ |
| Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)NCT05016882 / Novo Nordisk A/S | CompletedVerified 2025-11 | Phase 2698 actual | 0 recruiting255 listed / 24 countries | Dec 17, 2024actual | Nov 19, 2025ClinicalTrials.gov | Open NCT05016882 ↗ |
| A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With ObesityNCT05254158 / Novo Nordisk A/S | CompletedVerified 2023-11 | Phase 124 actual | 0 recruiting1 listed / 1 countries | Sep 7, 2022actual | Nov 7, 2023ClinicalTrials.gov | Open NCT05254158 ↗ |
| A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519 / REDEFINE 2 / Novo Nordisk A/S | CompletedVerified 2026-01 | Phase 31,200 actual | 0 recruiting179 listed / 13 countries | Jan 28, 2025actual | Jan 28, 2026ClinicalTrials.gov | Open NCT05394519 ↗ |
| A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the BodyNCT05564104 / Novo Nordisk A/S | CompletedVerified 2025-12 | Phase 132 actual | 0 recruiting4 listed / 3 countries | Sep 6, 2024actual | Dec 12, 2025ClinicalTrials.gov | Open NCT05564104 ↗ |
| A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy ParticipantsNCT05804162 / Novo Nordisk A/S | CompletedVerified 2024-10 | Phase 1107 actual | 0 recruiting1 listed / 1 countries | Aug 12, 2023actual | Nov 1, 2024ClinicalTrials.gov | Open NCT05804162 ↗ |
| A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightNCT05813925 / Novo Nordisk A/S | CompletedVerified 2026-01 | Phase 3331 actual | 0 recruiting28 listed / 2 countries | Jan 17, 2025actual | Jan 22, 2026ClinicalTrials.gov | Open NCT05813925 ↗ |
| A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightNCT05996848 / REDEFINE 6 / Novo Nordisk A/S | CompletedVerified 2026-01 | Phase 3300 actual | 0 recruiting37 listed / 1 countries | Jan 6, 2025actual | Jan 9, 2026ClinicalTrials.gov | Open NCT05996848 ↗ |
| A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 / REIMAGINE 2 / Novo Nordisk A/S | CompletedVerified 2026-07 | Phase 32,734 actual | 0 recruiting405 listed / 32 countries | Nov 19, 2025actual | Jul 8, 2026ClinicalTrials.gov | Open NCT06065540 ↗ |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 2626 actual | 0 recruiting128 listed / 13 countries | Sep 24, 2025actual | Apr 1, 2026ClinicalTrials.gov | Open NCT06131372 ↗ |
| A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNCT06131437 / Novo Nordisk A/S | CompletedVerified 2026-02 | Phase 3809 actual | 0 recruiting46 listed / 1 countries | Dec 8, 2025actual | Feb 6, 2026ClinicalTrials.gov | Open NCT06131437 ↗ |
| A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightNCT06207877 / Novo Nordisk A/S | CompletedVerified 2026-01 | Phase 162 actual | 0 recruiting1 listed / 1 countries | Oct 16, 2024actual | Jan 8, 2026ClinicalTrials.gov | Open NCT06207877 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 / Novo Nordisk A/S | CompletedVerified 2026-04 | Phase 31,024 actual | 0 recruiting196 listed / 8 countries | Mar 4, 2026actual | Apr 22, 2026ClinicalTrials.gov | Open NCT06221969 ↗ |
| A Study of How CagriSema Works on Appetite in People With Excess Body WeightNCT06267092 / Novo Nordisk A/S | CompletedVerified 2026-01 | Phase 1164 actual | 0 recruiting1 listed / 1 countries | Apr 7, 2025actual | Jan 8, 2026ClinicalTrials.gov | Open NCT06267092 ↗ |
| A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightNCT06289504 / Novo Nordisk A/S | CompletedVerified 2026-05 | Phase 134 actual | 0 recruiting1 listed / 1 countries | Oct 16, 2024actual | May 19, 2026ClinicalTrials.gov | Open NCT06289504 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161 / REIMAGINE 3 / Novo Nordisk A/S | CompletedVerified 2025-11 | Phase 3274 actual | 0 recruiting53 listed / 6 countries | Sep 9, 2025actual | Nov 28, 2025ClinicalTrials.gov | Open NCT06323161 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174 / REIMAGINE 1 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 3189 actual | 0 recruiting50 listed / 7 countries | Oct 1, 2025actual | Apr 2, 2026ClinicalTrials.gov | Open NCT06323174 ↗ |
| A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNCT06388187 / Novo Nordisk A/S | CompletedVerified 2026-05 | Phase 3300 actual | 0 recruiting25 listed / 5 countries | Apr 22, 2026actual | May 5, 2026ClinicalTrials.gov | Open NCT06388187 ↗ |
| Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 DiabetesNCT06403761 / Novo Nordisk A/S | CompletedVerified 2026-02 | Phase 1158 actual | 0 recruiting1 listed / 1 countries | Dec 28, 2025actual | Feb 27, 2026ClinicalTrials.gov | Open NCT06403761 ↗ |
| Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 2270 actual | 0 recruiting102 listed / 14 countries | Nov 21, 2025actual | Mar 12, 2026ClinicalTrials.gov | Open NCT06409130 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 / REIMAGINE 5 / Novo Nordisk A/S | CompletedVerified 2026-07 | Phase 31,023 actual | 0 recruiting163 listed / 14 countries | Jun 2, 2026actual | Jul 17, 2026ClinicalTrials.gov | Open NCT06534411 ↗ |
| A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityNCT06716307 / Novo Nordisk A/S | CompletedVerified 2025-08 | Phase 118 actual | 0 recruiting1 listed / 1 countries | Mar 28, 2025actual | Aug 27, 2025ClinicalTrials.gov | Open NCT06716307 ↗ |
| To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult ParticipantsNCT04389775 / XW003 / Sciwind Biosciences APAC CO Pty. Ltd. | CompletedVerified 2021-10 | Phase 164 actual | 0 recruiting1 listed / 1 countries | Sep 29, 2021actual | Oct 28, 2021ClinicalTrials.gov | Open NCT04389775 ↗ |
| Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With ObesityNCT05111912 / Sciwind Biosciences APAC CO Pty. Ltd. | CompletedVerified 2023-08 | Phase 2206 actual | 0 recruiting1 listed / 1 countries | Nov 16, 2022actual | Aug 21, 2023ClinicalTrials.gov | Open NCT05111912 ↗ |
| XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy AdultsNCT05184322 / Sciwind Biosciences APAC CO Pty. Ltd. | CompletedVerified 2024-11 | Phase 187 actual | 0 recruiting1 listed / 1 countries | Jul 13, 2024actual | Sep 10, 2025ClinicalTrials.gov | Open NCT05184322 ↗ |
| A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMNCT05680129 / Hangzhou Sciwind Biosciences Co., Ltd. | CompletedVerified 2023-07 | Phase 3623 actual | 0 recruiting1 listed / 1 countries | Jul 3, 2024actual | May 8, 2025ClinicalTrials.gov | Open NCT05680129 ↗ |
| A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM PatientsNCT05680155 / Hangzhou Sciwind Biosciences Co., Ltd. | CompletedVerified 2023-07 | Phase 3211 actual | 0 recruiting1 listed / 1 countries | Jun 12, 2024actual | Sep 10, 2025ClinicalTrials.gov | Open NCT05680155 ↗ |
| A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or ObesityNCT05813795 / Hangzhou Sciwind Biosciences Co., Ltd. | CompletedVerified 2024-07 | Phase 3664 actual | 0 recruiting1 listed / 1 countries | Jun 20, 2024actual | Apr 30, 2025ClinicalTrials.gov | Open NCT05813795 ↗ |
| A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or DigoxinNCT06335134 / Hangzhou Sciwind Biosciences Co., Ltd. | CompletedVerified 2023-07 | Phase 157 actual | 0 recruiting1 listed / 1 countries | Jan 8, 2024actual | May 8, 2025ClinicalTrials.gov | Open NCT06335134 ↗ |
| A Study of XW003 Injection in Chinese Adolescents With ObesityNCT07143227 / Hangzhou Sciwind Biosciences Co., Ltd. | CompletedVerified 2025-08 | Phase 148 actual | 0 recruiting1 listed / 1 countries | Apr 18, 2026actual | May 20, 2026ClinicalTrials.gov | Open NCT07143227 ↗ |
| A Study of LY3841136 in Healthy and Overweight ParticipantsNCT05295940 / Eli Lilly and Company | CompletedVerified 2024-03 | Phase 1148 actual | 0 recruiting3 listed / 1 countries | Jan 25, 2024actual | Apr 1, 2024ClinicalTrials.gov | Open NCT05295940 ↗ |
| A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06230523 / Eli Lilly and Company | CompletedVerified 2026-05Registry results posted | Phase 2263 actual | 0 recruiting43 listed / 1 countries | May 30, 2025actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06230523 ↗ |
| A Study of LY3841136 in Japanese Participants With Obesity or OverweightNCT06297616 / Eli Lilly and Company | CompletedVerified 2026-01 | Phase 1128 actual | 0 recruiting3 listed / 1 countries | Nov 21, 2025actual | Jan 16, 2026ClinicalTrials.gov | Open NCT06297616 ↗ |
| A Study of LY3841136 in Overweight and Obese ParticipantsNCT06345066 / Eli Lilly and Company | CompletedVerified 2025-10 | Phase 196 actual | 0 recruiting3 listed / 1 countries | Sep 29, 2025actual | Oct 15, 2025ClinicalTrials.gov | Open NCT06345066 ↗ |
| A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityNCT06916065 / Eli Lilly and Company | CompletedVerified 2026-01 | Phase 1188 actual | 0 recruiting3 listed / 1 countries | Jan 19, 2026actual | Jan 30, 2026ClinicalTrials.gov | Open NCT06916065 ↗ |
| A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or OverweightNCT06916091 / Eli Lilly and Company | CompletedVerified 2025-11 | Phase 130 actual | 0 recruiting1 listed / 1 countries | Sep 9, 2025actual | Nov 19, 2025ClinicalTrials.gov | Open NCT06916091 ↗ |
| A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes MellitusNCT04838405 / Carmot Therapeutics, Inc. | CompletedVerified 2025-10 | Phase 1129 actual | 0 recruiting2 listed / 2 countries | Jun 18, 2024actual | Oct 20, 2025ClinicalTrials.gov | Open NCT04838405 ↗ |
| A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityNCT06525935 / Carmot Therapeutics, Inc. | CompletedVerified 2026-04 | Phase 2469 actual | 0 recruiting34 listed / 1 countries | Dec 8, 2025actual | Apr 17, 2026ClinicalTrials.gov | Open NCT06525935 ↗ |
| Single and Multiple Ascending Dose Study of AMG 133 in Participants With ObesityNCT04478708 / Amgen | CompletedVerified 2025-11Registry results posted | Phase 1110 actual | 0 recruiting3 listed / 1 countries | Nov 18, 2022actual | Dec 10, 2025ClinicalTrials.gov | Open NCT04478708 ↗ |
| Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian ParticipantsNCT05056246 / Amgen | CompletedVerified 2025-01Registry results posted | Phase 134 actual | 0 recruiting1 listed / 1 countries | Apr 8, 2022actual | Feb 25, 2025ClinicalTrials.gov | Open NCT05056246 ↗ |
| Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusNCT05669599 / Amgen | CompletedVerified 2026-01 | Phase 2592 actual | 0 recruiting78 listed / 12 countries | Oct 8, 2024actual | Jan 20, 2026ClinicalTrials.gov | Open NCT05669599 ↗ |
| A Study to Evaluate AMG 133 in Chinese Participants With Obesity or OverweightNCT06352892 / Amgen | CompletedVerified 2026-01 | Phase 120 actual | 0 recruiting1 listed / 1 countries | Aug 27, 2024actual | Jan 8, 2026ClinicalTrials.gov | Open NCT06352892 ↗ |
| A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or ObesityNCT06976372 / Amgen | CompletedVerified 2025-10 | Phase 1120 actual | 0 recruiting3 listed / 1 countries | Dec 27, 2024actual | Oct 8, 2025ClinicalTrials.gov | Open NCT06976372 ↗ |
| Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsNCT07226778 / Amgen | CompletedVerified 2026-06 | Phase 1348 actual | 0 recruiting4 listed / 1 countries | May 28, 2026actual | Jun 17, 2026ClinicalTrials.gov | Open NCT07226778 ↗ |
| A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or ObesityNCT07310563 / Amgen | CompletedVerified 2025-12 | Phase 159 actual | 0 recruiting1 listed / 1 countries | May 9, 2025actual | Dec 30, 2025ClinicalTrials.gov | Open NCT07310563 ↗ |
| A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsNCT07313761 / Amgen | CompletedVerified 2026-07 | Phase 1349 actual | 0 recruiting4 listed / 1 countries | Jun 26, 2026actual | Jul 16, 2026ClinicalTrials.gov | Open NCT07313761 ↗ |
| A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic FunctionNCT07428525 / Amgen | CompletedVerified 2026-03 | Phase 136 actual | 0 recruiting5 listed / 1 countries | Feb 26, 2026actual | Mar 11, 2026ClinicalTrials.gov | Open NCT07428525 ↗ |
| The Effect of AMG 133 on Gastric EmptyingNCT07429032 / Amgen | CompletedVerified 2025-12 | Phase 157 actual | 0 recruiting1 listed / 1 countries | Nov 26, 2025actual | Feb 24, 2026ClinicalTrials.gov | Open NCT07429032 ↗ |
| A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the BodyNCT07429045 / Amgen | CompletedVerified 2025-12 | Phase 144 actual | 0 recruiting5 listed / 1 countries | Nov 21, 2025actual | Feb 24, 2026ClinicalTrials.gov | Open NCT07429045 ↗ |
| A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityNCT07717814 / Amgen | CompletedVerified 2026-07 | Phase 1154 actual | 0 recruiting4 listed / 1 countries | May 22, 2025actual | Jul 21, 2026ClinicalTrials.gov | Open NCT07717814 ↗ |
| A Study of LY3305677 in Healthy ParticipantsNCT02972645 / Eli Lilly and Company | CompletedVerified 2017-07 | Phase 166 actual | 0 recruiting1 listed / 1 countries | Jul 14, 2017actual | Jul 24, 2017ClinicalTrials.gov | Open NCT02972645 ↗ |
| A Study of Multiple Doses of LY3305677 in Healthy ParticipantsNCT03325387 / Eli Lilly and Company | CompletedVerified 2018-08 | Phase 156 actual | 0 recruiting1 listed / 1 countries | Aug 3, 2018actual | Aug 16, 2018ClinicalTrials.gov | Open NCT03325387 ↗ |
| A Study of LY3305677 in Participants With Type 2 DiabetesNCT03928379 / Eli Lilly and Company | CompletedVerified 2021-07 | Phase 124 actual | 0 recruiting1 listed / 1 countries | Jul 8, 2021actual | Jul 19, 2021ClinicalTrials.gov | Open NCT03928379 ↗ |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity SubjectsNCT04440345 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2023-11 | Phase 1 / Phase 260 actual | 0 recruiting1 listed / 1 countries | Jun 16, 2021actual | Nov 28, 2023ClinicalTrials.gov | Open NCT04440345 ↗ |
| Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DMNCT04466904 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2021-07 | Phase 1 / Phase 242 actual | 0 recruiting1 listed / 1 countries | May 28, 2021actual | Jul 23, 2021ClinicalTrials.gov | Open NCT04466904 ↗ |
| Clinical Study of IBI362 in Healthy Chinese Male SubjectsNCT04773977 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2021-03 | Phase 124 actual | 0 recruiting1 listed / 1 countries | Mar 9, 2021actual | Jul 8, 2021ClinicalTrials.gov | Open NCT04773977 ↗ |
| A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsNCT04904913 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2025-11 | Phase 2328 actual | 0 recruiting1 listed / 1 countries | Mar 29, 2023actual | Nov 17, 2025ClinicalTrials.gov | Open NCT04904913 ↗ |
| A Study of IBI362 in Chinese Patients With Type 2 DiabetesNCT04965506 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2023-12 | Phase 2252 actual | 0 recruiting1 listed / 1 countries | Apr 28, 2022actual | Dec 27, 2023ClinicalTrials.gov | Open NCT04965506 ↗ |
| A Study of IBI362 in Participants With Type 2 DiabetesNCT05606913 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2024-08 | Phase 3731 actual | 0 recruiting1 listed / 1 countries | Jan 26, 2024actual | Aug 23, 2024ClinicalTrials.gov | Open NCT05606913 ↗ |
| A Study of IBI362 in Participants With Obesity or OverweightNCT05607680 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2024-11 | Phase 3610 actual | 0 recruiting23 listed / 1 countries | Aug 21, 2023actual | Nov 12, 2024ClinicalTrials.gov | Open NCT05607680 ↗ |
| A Study of LY3305677 in Participants With Obesity Or OverweightNCT05623839 / Eli Lilly and Company | CompletedVerified 2023-07 | Phase 132 actual | 0 recruiting3 listed / 1 countries | Jun 27, 2023actual | Jul 5, 2023ClinicalTrials.gov | Open NCT05623839 ↗ |
| A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseNCT05628311 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2024-08 | Phase 3319 actual | 0 recruiting1 listed / 1 countries | Oct 25, 2023actual | Aug 20, 2024ClinicalTrials.gov | Open NCT05628311 ↗ |
| Pharmacokinetics of IBI362 in Subjects With and Without Renal ImpairmentNCT05793450 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2024-02 | Phase 120 actual | 0 recruiting1 listed / 1 countries | Sep 18, 2023actual | Feb 20, 2024ClinicalTrials.gov | Open NCT05793450 ↗ |
| A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese SubjectsNCT05815680 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2023-11 | Phase 148 actual | 0 recruiting1 listed / 1 countries | Aug 18, 2023actual | Nov 14, 2023ClinicalTrials.gov | Open NCT05815680 ↗ |
| A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06124807 / Eli Lilly and Company | CompletedVerified 2026-03Registry results posted | Phase 2179 actual | 0 recruiting29 listed / 1 countries | Jan 22, 2025actual | Apr 21, 2026ClinicalTrials.gov | Open NCT06124807 ↗ |
| A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityNCT06184568 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2026-06 | Phase 3349 actual | 0 recruiting1 listed / 1 countries | Sep 17, 2025actual | Jun 11, 2026ClinicalTrials.gov | Open NCT06184568 ↗ |
| This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With ObesityNCT06536023 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2025-09 | Phase 136 actual | 0 recruiting1 listed / 1 countries | Jul 22, 2025actual | Sep 12, 2025ClinicalTrials.gov | Open NCT06536023 ↗ |
| A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderNCT06817356 / Eli Lilly and Company | CompletedVerified 2026-07 | Phase 2308 actual | 0 recruiting25 listed / 1 countries | Mar 19, 2026actual | Jul 16, 2026ClinicalTrials.gov | Open NCT06817356 ↗ |
| ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityNCT04561245 / Altimmune, Inc. | CompletedVerified 2025-06 | Phase 1100 actual | 0 recruiting1 listed / 1 countries | Oct 29, 2021actual | Jun 24, 2025ClinicalTrials.gov | Open NCT04561245 ↗ |
| Pemvidutide (ALT-801) DDI Study in Healthy VolunteersNCT04972396 / Altimmune, Inc. | CompletedVerified 2025-06 | Phase 140 actual | 0 recruiting2 listed / 1 countries | May 15, 2022actual | Jun 24, 2025ClinicalTrials.gov | Open NCT04972396 ↗ |
| ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)NCT05006885 / Altimmune, Inc. | CompletedVerified 2023-07 | Phase 195 actual | 0 recruiting15 listed / 1 countries | Aug 17, 2022actual | Jul 27, 2023ClinicalTrials.gov | Open NCT05006885 ↗ |
| ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)NCT05134662 / Altimmune, Inc. | CompletedVerified 2025-06 | Phase 155 actual | 0 recruiting7 listed / 1 countries | Feb 3, 2023actual | Jun 24, 2025ClinicalTrials.gov | Open NCT05134662 ↗ |
| Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)NCT05292911 / Altimmune, Inc. | CompletedVerified 2022-10 | Phase 164 actual | 0 recruiting13 listed / 1 countries | Oct 31, 2022actual | Jul 27, 2023ClinicalTrials.gov | Open NCT05292911 ↗ |
| Efficacy and Safety of ALT-801 in the Treatment of ObesityNCT05295875 / Altimmune, Inc. | CompletedVerified 2023-11 | Phase 2391 actual | 0 recruiting31 listed / 1 countries | Sep 28, 2023actual | Nov 29, 2023ClinicalTrials.gov | Open NCT05295875 ↗ |
| IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)NCT05989711 / IMPACT / Altimmune, Inc. | CompletedVerified 2026-05 | Phase 2212 actual | 0 recruiting40 listed / 3 countries | Nov 25, 2025actual | May 18, 2026ClinicalTrials.gov | Open NCT05989711 ↗ |
| A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial ParticipantsNCT05096598 / Zealand Pharma | CompletedVerified 2023-01 | Phase 164 actual | 0 recruiting1 listed / 1 countries | Jan 12, 2023actual | Jan 17, 2023ClinicalTrials.gov | Open NCT05096598 ↗ |
| A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy ParticipantsNCT05613387 / Zealand Pharma | CompletedVerified 2024-06 | Phase 168 actual | 0 recruiting1 listed / 1 countries | Jun 13, 2024actual | Jun 18, 2024ClinicalTrials.gov | Open NCT05613387 ↗ |
| Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbiditiesNCT06662539 / ZUPREME / Zealand Pharma | CompletedVerified 2026-03 | Phase 2493 actual | 0 recruiting32 listed / 3 countries | Sep 30, 2025actual | Mar 23, 2026ClinicalTrials.gov | Open NCT06662539 ↗ |
| Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal FunctionNCT07076030 / Zealand Pharma | CompletedVerified 2026-01 | Phase 139 actual | 0 recruiting1 listed / 1 countries | Nov 25, 2025actual | Jan 28, 2026ClinicalTrials.gov | Open NCT07076030 ↗ |
| Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product ConcentrationsNCT07338214 / Zealand Pharma | CompletedVerified 2026-04 | Phase 148 actual | 0 recruiting1 listed / 1 countries | Mar 31, 2026actual | Apr 8, 2026ClinicalTrials.gov | Open NCT07338214 ↗ |
| A Safety Study of LY3437943 Given as a Single Injection in Healthy ParticipantsNCT03841630 / Eli Lilly and Company | CompletedVerified 2019-08 | Phase 145 actual | 0 recruiting1 listed / 1 countries | Jul 25, 2019actual | Aug 6, 2019ClinicalTrials.gov | Open NCT03841630 ↗ |
| A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)NCT04143802 / Eli Lilly and Company | CompletedVerified 2021-01-15 | Phase 172 actual | 0 recruiting4 listed / 1 countries | Dec 28, 2020actual | Jan 20, 2021ClinicalTrials.gov | Open NCT04143802 ↗ |
| A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)NCT04823208 / Eli Lilly and Company | CompletedVerified 2022-08 | Phase 164 actual | 0 recruiting4 listed / 1 countries | Jun 23, 2022actual | Aug 22, 2022ClinicalTrials.gov | Open NCT04823208 ↗ |
| A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785 / Eli Lilly and Company | CompletedVerified 2023-06Registry results posted | Phase 2281 actual | 0 recruiting43 listed / 2 countries | Jul 8, 2022actual | Jul 3, 2023ClinicalTrials.gov | Open NCT04867785 ↗ |
| A Study of LY3437943 in Participants Who Have Obesity or Are OverweightNCT04881760 / Eli Lilly and Company | CompletedVerified 2023-08Registry results posted | Phase 2338 actual | 0 recruiting28 listed / 2 countries | May 16, 2022actual | Sep 13, 2023ClinicalTrials.gov | Open NCT04881760 ↗ |
| A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232 / Eli Lilly and Company | CompletedVerified 2023-04-01 | Phase 132 actual | 0 recruiting2 listed / 1 countries | Feb 24, 2023actual | Apr 18, 2023ClinicalTrials.gov | Open NCT05445232 ↗ |
| A Study of LY3437943 in Chinese Participants With Obesity Or OverweightNCT05548231 / Eli Lilly and Company | CompletedVerified 2023-08 | Phase 132 actual | 0 recruiting2 listed / 1 countries | Jul 27, 2023actual | Aug 14, 2023ClinicalTrials.gov | Open NCT05548231 ↗ |
| A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal FunctionNCT05611957 / Eli Lilly and Company | CompletedVerified 2023-09-15 | Phase 129 actual | 0 recruiting4 listed / 1 countries | Sep 5, 2023actual | Oct 2, 2023ClinicalTrials.gov | Open NCT05611957 ↗ |
| A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male ParticipantsNCT05757531 / Eli Lilly and Company | CompletedVerified 2023-07 | Phase 17 actual | 0 recruiting1 listed / 1 countries | Jun 23, 2023actual | Jul 5, 2023ClinicalTrials.gov | Open NCT05757531 ↗ |
| A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionNCT05916560 / Eli Lilly and Company | CompletedVerified 2025-04 | Phase 143 actual | 0 recruiting5 listed / 1 countries | Mar 2, 2025actual | Apr 18, 2025ClinicalTrials.gov | Open NCT05916560 ↗ |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 / TRIUMPH-1 / Eli Lilly and Company | CompletedVerified 2026-06 | Phase 32,335 actual | 0 recruiting134 listed / 12 countries | Apr 6, 2026actual | Jun 3, 2026ClinicalTrials.gov | Open NCT05929066 ↗ |
| A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 / TRIUMPH-4 / Eli Lilly and Company | CompletedVerified 2026-01 | Phase 3445 actual | 0 recruiting49 listed / 6 countries | Nov 14, 2025actual | Jan 21, 2026ClinicalTrials.gov | Open NCT05931367 ↗ |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 / Eli Lilly and Company | CompletedVerified 2025-11 | Phase 2146 actual | 0 recruiting42 listed / 5 countries | Oct 1, 2025actual | Nov 25, 2025ClinicalTrials.gov | Open NCT05936151 ↗ |
| A Study of LY3437943 in Healthy Participants With a High Body Mass IndexNCT05959096 / Eli Lilly and Company | CompletedVerified 2024-09 | Phase 185 actual | 0 recruiting1 listed / 1 countries | Jul 25, 2024actual | Oct 1, 2024ClinicalTrials.gov | Open NCT05959096 ↗ |
| A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection DevicesNCT06003465 / Eli Lilly and Company | CompletedVerified 2024-03 | Phase 157 actual | 0 recruiting3 listed / 1 countries | Feb 8, 2024actual | Mar 29, 2024ClinicalTrials.gov | Open NCT06003465 ↗ |
| A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseNCT06039826 / Eli Lilly and Company | CompletedVerified 2024-07 | Phase 146 actual | 0 recruiting2 listed / 1 countries | Jul 11, 2024actual | Jul 26, 2024ClinicalTrials.gov | Open NCT06039826 ↗ |
| A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943NCT06313528 / Eli Lilly and Company | CompletedVerified 2025-09 | Phase 185 actual | 0 recruiting3 listed / 1 countries | Aug 26, 2025actual | Sep 23, 2025ClinicalTrials.gov | Open NCT06313528 ↗ |
| Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 / Eli Lilly and Company | CompletedVerified 2026-03 | Phase 3537 actual | 0 recruiting48 listed / 4 countries | Jan 22, 2026actual | Mar 5, 2026ClinicalTrials.gov | Open NCT06354660 ↗ |
| To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsNCT06808802 / Eli Lilly and Company | CompletedVerified 2025-06 | Phase 130 actual | 0 recruiting1 listed / 1 countries | Apr 15, 2025actual | Jun 5, 2025ClinicalTrials.gov | Open NCT06808802 ↗ |
| A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846 / Eli Lilly and Company | CompletedVerified 2026-06 | Phase 180 actual | 0 recruiting1 listed / 1 countries | May 4, 2026actual | Jun 18, 2026ClinicalTrials.gov | Open NCT06982846 ↗ |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male VolunteersNCT03175211 / Boehringer Ingelheim | CompletedVerified 2018-02 | Phase 120 actual | 0 recruiting1 listed / 1 countries | Feb 19, 2018actual | Jul 16, 2018ClinicalTrials.gov | Open NCT03175211 ↗ |
| A Study to Test Different Doses of BI 456906 in Patients With ObesityNCT03591718 / Boehringer Ingelheim | CompletedVerified 2021-03 | Phase 1131 actual | 0 recruiting2 listed / 1 countries | Apr 20, 2020actual | Mar 22, 2021ClinicalTrials.gov | Open NCT03591718 ↗ |
| A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.NCT04153929 / Boehringer Ingelheim | CompletedVerified 2022-11Registry results posted | Phase 2413 actual | 0 recruiting80 listed / 14 countries | Oct 8, 2021actual | Nov 29, 2022ClinicalTrials.gov | Open NCT04153929 ↗ |
| A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2NCT04384081 / Boehringer Ingelheim | CompletedVerified 2021-01 | Phase 137 actual | 0 recruiting1 listed / 1 countries | Nov 17, 2020actual | Jan 26, 2021ClinicalTrials.gov | Open NCT04384081 ↗ |
| A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightNCT04667377 / Boehringer Ingelheim | CompletedVerified 2023-10Registry results posted | Phase 2387 actual | 0 recruiting43 listed / 12 countries | Sep 15, 2022actual | Nov 2, 2023ClinicalTrials.gov | Open NCT04667377 ↗ |
| A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)NCT04771273 / Boehringer Ingelheim | CompletedVerified 2024-11Registry results posted | Phase 2295 actual | 0 recruiting154 listed / 25 countries | Nov 9, 2023actual | Dec 3, 2024ClinicalTrials.gov | Open NCT04771273 ↗ |
| A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906NCT05296733 / Boehringer Ingelheim | CompletedVerified 2024-08 | Phase 182 actual | 0 recruiting13 listed / 6 countries | Dec 29, 2023actual | Aug 15, 2024ClinicalTrials.gov | Open NCT05296733 ↗ |
| A Study in Healthy Men to Test How BI 456906 is Processed in the BodyNCT05421338 / Boehringer Ingelheim | CompletedVerified 2022-12 | Phase 16 actual | 0 recruiting1 listed / 1 countries | Nov 17, 2022actual | Dec 14, 2022ClinicalTrials.gov | Open NCT05421338 ↗ |
| A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906NCT05751226 / Boehringer Ingelheim | CompletedVerified 2025-01 | Phase 188 actual | 0 recruiting1 listed / 1 countries | Aug 1, 2024actual | Jan 22, 2025ClinicalTrials.gov | Open NCT05751226 ↗ |
| A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the BloodNCT05896384 / Boehringer Ingelheim | CompletedVerified 2025-04 | Phase 132 actual | 0 recruiting1 listed / 1 countries | Feb 14, 2025actual | Apr 16, 2025ClinicalTrials.gov | Open NCT05896384 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT06066515 / SYNCHRONIZE™-1 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 3726 actual | 0 recruiting118 listed / 14 countries | Dec 2, 2025actual | Mar 12, 2026ClinicalTrials.gov | Open NCT06066515 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 / SYNCHRONIZE™-2 / Boehringer Ingelheim | CompletedVerified 2026-06 | Phase 3755 actual | 0 recruiting143 listed / 19 countries | Dec 12, 2025actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06066528 ↗ |
| A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 / Boehringer Ingelheim | CompletedVerified 2026-07 | Phase 35,531 actual | 0 recruiting540 listed / 35 countries | Jun 1, 2026actual | Jul 23, 2026ClinicalTrials.gov | Open NCT06077864 ↗ |
| A Study to Test Whether Survodutide Helps Japanese People Living With Obesity DiseaseNCT06176365 / SYNCHRONIZE™JP / Boehringer Ingelheim | CompletedVerified 2026-04 | Phase 3274 actual | 0 recruiting28 listed / 1 countries | Dec 3, 2025actual | Apr 30, 2026ClinicalTrials.gov | Open NCT06176365 ↗ |
| A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityNCT06200467 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 1110 actual | 0 recruiting1 listed / 1 countries | Oct 22, 2025actual | Mar 13, 2026ClinicalTrials.gov | Open NCT06200467 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightNCT06214741 / Boehringer Ingelheim | CompletedVerified 2026-04 | Phase 3307 actual | 0 recruiting28 listed / 1 countries | Jul 29, 2025actual | Apr 30, 2026ClinicalTrials.gov | Open NCT06214741 ↗ |
| A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)NCT06309992 / Boehringer Ingelheim | CompletedVerified 2026-04 | Phase 3218 actual | 0 recruiting37 listed / 2 countries | Oct 9, 2025actual | Apr 30, 2026ClinicalTrials.gov | Open NCT06309992 ↗ |
| A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney ProblemsNCT06352411 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 142 actual | 0 recruiting2 listed / 1 countries | Sep 16, 2025actual | Mar 13, 2026ClinicalTrials.gov | Open NCT06352411 ↗ |
| A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain ActivityNCT06352424 / Boehringer Ingelheim | CompletedVerified 2025-03 | Phase 123 actual | 0 recruiting1 listed / 1 countries | Feb 24, 2025actual | Mar 12, 2025ClinicalTrials.gov | Open NCT06352424 ↗ |
| A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the BodyNCT06492135 / Boehringer Ingelheim | CompletedVerified 2025-04 | Phase 130 actual | 0 recruiting1 listed / 1 countries | Apr 15, 2025actual | Apr 23, 2025ClinicalTrials.gov | Open NCT06492135 ↗ |
| A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or ObesityNCT06564441 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 134 actual | 0 recruiting1 listed / 1 countries | Dec 16, 2025actual | Mar 13, 2026ClinicalTrials.gov | Open NCT06564441 ↗ |
| A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the BodyNCT06772532 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 130 actual | 0 recruiting1 listed / 1 countries | May 29, 2025actual | Mar 13, 2026ClinicalTrials.gov | Open NCT06772532 ↗ |
| A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the BodyNCT07071974 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 116 actual | 0 recruiting1 listed / 1 countries | Oct 7, 2025actual | Mar 13, 2026ClinicalTrials.gov | Open NCT07071974 ↗ |
| A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorNCT07413913 / Boehringer Ingelheim | CompletedVerified 2026-06 | Phase 156 actual | 0 recruiting1 listed / 1 countries | May 28, 2026actual | Jun 15, 2026ClinicalTrials.gov | Open NCT07413913 ↗ |
| Phase 1 Study to Evaluate the Safety and Tolerability of VK2735NCT05203237 / Viking Therapeutics, Inc. | CompletedVerified 2025-02 | Phase 192 actual | 0 recruiting1 listed / 1 countries | Nov 4, 2024actual | Feb 17, 2025ClinicalTrials.gov | Open NCT05203237 ↗ |
| VK2735 for Weight Management Phase 2NCT06068946 / VENTURE / Viking Therapeutics, Inc. | CompletedVerified 2024-12 | Phase 2176 actual | 0 recruiting20 listed / 1 countries | Feb 27, 2024actual | Feb 12, 2025ClinicalTrials.gov | Open NCT06068946 ↗ |
| VK2735 for Weight Management Phase 2 (Venture Oral Dosing)NCT06828055 / Viking Therapeutics, Inc. | CompletedVerified 2025-09 | Phase 2280 actual | 0 recruiting15 listed / 1 countries | Jun 24, 2025actual | Oct 6, 2025ClinicalTrials.gov | Open NCT06828055 ↗ |
| A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740 / Novo Nordisk A/S | WithdrawnVerified 2026-07 | Phase 20 actual | 0 recruiting61 listed / 8 countries | Aug 25, 2027estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07357740 ↗ |
| A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766 / Novo Nordisk A/S | WithdrawnVerified 2026-07 | Phase 30 actual | 0 recruiting116 listed / 14 countries | Nov 29, 2027estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07357766 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →